KIT and gastrointestinal stromal tumor: In most cases of GIST, secondary KIT mutations reactivate KIT downstream signaling pathways, such as the PI3K/AKT/mTOR pathway, and continue to drive GIST proliferation and survival, leading to acquired IM resistance (23–27).